Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)

Wajeh Y Qunibi, Robert E. Hootkins, Laveta L. McDowell, Micah S. Meyer, Matthias Simon, Rodolfo O. Garza, Russell W. Pelham, Mark V B Cleveland, Larry R. Muenz, David Y. He, Charles R. Nolan

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

Background. Hyperphosphatemia underlies development of hyperparathyroidism, osteodystrophy, extraosseous calcification, and is associated with increased mortality in hemodialysis patients Methods. To determine whether calcium acetate or sevelamer hydrochloride best achieves recently recommended treatment goals of phosphorus ≤5.5 mg/dL and Ca x P product ≤55 mg2/dL 2, we conducted an 8-week randomized, double-blind study in 100 hemodialysis patients. Results. Comparisons of time-averaged concentrations (weeks 1 to 8) demonstrated that calcium acetate recipients had lower serum phosphorus (1.08 mg/dL difference, P = 0.0006), higher serum calcium (0.63 mg/dL difference, P < 0.0001), and lower Ca x P (6.1 mg2/dL2 difference, P = 0.022) than sevelamer recipients. At each week, calcium acetate recipients were 20% to 24% more likely to attain goal phosphorus [odds ratio (OR) 2.37, 95% CI 1.28-4.37, P = 0.0058], and 15% to 20% more likely to attain goal Ca x P (OR 2.16, 95% CI 1.20-3.86, P = 0.0097). Transient hypercalcemia occurred in 8 of 48 (16.7%) calcium acetate recipients, all of whom received concomitant intravenous vitamin D. By regression analysis hypercalcemia was more likely with calcium acetate (OR 6.1, 95% CI 2.8-13.3, P < 0.0001). Week 8 intact PTH levels were not significantly different. Serum bicarbonate levels were significantly lower with sevelamer hydrochloride treatment (P < 0.0001). Conclusion. Calcium acetate controls serum phosphorus and calcium-phosphate product more effectively than sevelamer hydrochloride. Cost-benefit analysis indicates that in the absence of hypercalcemia, calcium acetate should remain the treatment of choice for hyperphosphatemia in hemodialysis patients.

Original languageEnglish (US)
Pages (from-to)1914-1926
Number of pages13
JournalKidney International
Volume65
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

calcium acetate
Hyperphosphatemia
Renal Dialysis
Phosphorus
Hypercalcemia
Odds Ratio
Serum
Therapeutics
Hyperparathyroidism
Bicarbonates
Sevelamer
Double-Blind Method
Vitamin D
Cost-Benefit Analysis

Keywords

  • Calcium acetate
  • Hypercalcemia
  • Hyperphosphatemia
  • Hypocalcemia
  • Metabolic acidosis
  • Sevelamer hydrochloride

ASJC Scopus subject areas

  • Nephrology

Cite this

Qunibi, W. Y., Hootkins, R. E., McDowell, L. L., Meyer, M. S., Simon, M., Garza, R. O., ... Nolan, C. R. (2004). Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney International, 65(5), 1914-1926. https://doi.org/10.1111/j.1523-1755.2004.00590.x

Treatment of hyperphosphatemia in hemodialysis patients : The Calcium Acetate Renagel Evaluation (CARE Study). / Qunibi, Wajeh Y; Hootkins, Robert E.; McDowell, Laveta L.; Meyer, Micah S.; Simon, Matthias; Garza, Rodolfo O.; Pelham, Russell W.; Cleveland, Mark V B; Muenz, Larry R.; He, David Y.; Nolan, Charles R.

In: Kidney International, Vol. 65, No. 5, 05.2004, p. 1914-1926.

Research output: Contribution to journalArticle

Qunibi, WY, Hootkins, RE, McDowell, LL, Meyer, MS, Simon, M, Garza, RO, Pelham, RW, Cleveland, MVB, Muenz, LR, He, DY & Nolan, CR 2004, 'Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)', Kidney International, vol. 65, no. 5, pp. 1914-1926. https://doi.org/10.1111/j.1523-1755.2004.00590.x
Qunibi, Wajeh Y ; Hootkins, Robert E. ; McDowell, Laveta L. ; Meyer, Micah S. ; Simon, Matthias ; Garza, Rodolfo O. ; Pelham, Russell W. ; Cleveland, Mark V B ; Muenz, Larry R. ; He, David Y. ; Nolan, Charles R. / Treatment of hyperphosphatemia in hemodialysis patients : The Calcium Acetate Renagel Evaluation (CARE Study). In: Kidney International. 2004 ; Vol. 65, No. 5. pp. 1914-1926.
@article{9bfb87b0829d444380475665d8f1e19f,
title = "Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)",
abstract = "Background. Hyperphosphatemia underlies development of hyperparathyroidism, osteodystrophy, extraosseous calcification, and is associated with increased mortality in hemodialysis patients Methods. To determine whether calcium acetate or sevelamer hydrochloride best achieves recently recommended treatment goals of phosphorus ≤5.5 mg/dL and Ca x P product ≤55 mg2/dL 2, we conducted an 8-week randomized, double-blind study in 100 hemodialysis patients. Results. Comparisons of time-averaged concentrations (weeks 1 to 8) demonstrated that calcium acetate recipients had lower serum phosphorus (1.08 mg/dL difference, P = 0.0006), higher serum calcium (0.63 mg/dL difference, P < 0.0001), and lower Ca x P (6.1 mg2/dL2 difference, P = 0.022) than sevelamer recipients. At each week, calcium acetate recipients were 20{\%} to 24{\%} more likely to attain goal phosphorus [odds ratio (OR) 2.37, 95{\%} CI 1.28-4.37, P = 0.0058], and 15{\%} to 20{\%} more likely to attain goal Ca x P (OR 2.16, 95{\%} CI 1.20-3.86, P = 0.0097). Transient hypercalcemia occurred in 8 of 48 (16.7{\%}) calcium acetate recipients, all of whom received concomitant intravenous vitamin D. By regression analysis hypercalcemia was more likely with calcium acetate (OR 6.1, 95{\%} CI 2.8-13.3, P < 0.0001). Week 8 intact PTH levels were not significantly different. Serum bicarbonate levels were significantly lower with sevelamer hydrochloride treatment (P < 0.0001). Conclusion. Calcium acetate controls serum phosphorus and calcium-phosphate product more effectively than sevelamer hydrochloride. Cost-benefit analysis indicates that in the absence of hypercalcemia, calcium acetate should remain the treatment of choice for hyperphosphatemia in hemodialysis patients.",
keywords = "Calcium acetate, Hypercalcemia, Hyperphosphatemia, Hypocalcemia, Metabolic acidosis, Sevelamer hydrochloride",
author = "Qunibi, {Wajeh Y} and Hootkins, {Robert E.} and McDowell, {Laveta L.} and Meyer, {Micah S.} and Matthias Simon and Garza, {Rodolfo O.} and Pelham, {Russell W.} and Cleveland, {Mark V B} and Muenz, {Larry R.} and He, {David Y.} and Nolan, {Charles R.}",
year = "2004",
month = "5",
doi = "10.1111/j.1523-1755.2004.00590.x",
language = "English (US)",
volume = "65",
pages = "1914--1926",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Treatment of hyperphosphatemia in hemodialysis patients

T2 - The Calcium Acetate Renagel Evaluation (CARE Study)

AU - Qunibi, Wajeh Y

AU - Hootkins, Robert E.

AU - McDowell, Laveta L.

AU - Meyer, Micah S.

AU - Simon, Matthias

AU - Garza, Rodolfo O.

AU - Pelham, Russell W.

AU - Cleveland, Mark V B

AU - Muenz, Larry R.

AU - He, David Y.

AU - Nolan, Charles R.

PY - 2004/5

Y1 - 2004/5

N2 - Background. Hyperphosphatemia underlies development of hyperparathyroidism, osteodystrophy, extraosseous calcification, and is associated with increased mortality in hemodialysis patients Methods. To determine whether calcium acetate or sevelamer hydrochloride best achieves recently recommended treatment goals of phosphorus ≤5.5 mg/dL and Ca x P product ≤55 mg2/dL 2, we conducted an 8-week randomized, double-blind study in 100 hemodialysis patients. Results. Comparisons of time-averaged concentrations (weeks 1 to 8) demonstrated that calcium acetate recipients had lower serum phosphorus (1.08 mg/dL difference, P = 0.0006), higher serum calcium (0.63 mg/dL difference, P < 0.0001), and lower Ca x P (6.1 mg2/dL2 difference, P = 0.022) than sevelamer recipients. At each week, calcium acetate recipients were 20% to 24% more likely to attain goal phosphorus [odds ratio (OR) 2.37, 95% CI 1.28-4.37, P = 0.0058], and 15% to 20% more likely to attain goal Ca x P (OR 2.16, 95% CI 1.20-3.86, P = 0.0097). Transient hypercalcemia occurred in 8 of 48 (16.7%) calcium acetate recipients, all of whom received concomitant intravenous vitamin D. By regression analysis hypercalcemia was more likely with calcium acetate (OR 6.1, 95% CI 2.8-13.3, P < 0.0001). Week 8 intact PTH levels were not significantly different. Serum bicarbonate levels were significantly lower with sevelamer hydrochloride treatment (P < 0.0001). Conclusion. Calcium acetate controls serum phosphorus and calcium-phosphate product more effectively than sevelamer hydrochloride. Cost-benefit analysis indicates that in the absence of hypercalcemia, calcium acetate should remain the treatment of choice for hyperphosphatemia in hemodialysis patients.

AB - Background. Hyperphosphatemia underlies development of hyperparathyroidism, osteodystrophy, extraosseous calcification, and is associated with increased mortality in hemodialysis patients Methods. To determine whether calcium acetate or sevelamer hydrochloride best achieves recently recommended treatment goals of phosphorus ≤5.5 mg/dL and Ca x P product ≤55 mg2/dL 2, we conducted an 8-week randomized, double-blind study in 100 hemodialysis patients. Results. Comparisons of time-averaged concentrations (weeks 1 to 8) demonstrated that calcium acetate recipients had lower serum phosphorus (1.08 mg/dL difference, P = 0.0006), higher serum calcium (0.63 mg/dL difference, P < 0.0001), and lower Ca x P (6.1 mg2/dL2 difference, P = 0.022) than sevelamer recipients. At each week, calcium acetate recipients were 20% to 24% more likely to attain goal phosphorus [odds ratio (OR) 2.37, 95% CI 1.28-4.37, P = 0.0058], and 15% to 20% more likely to attain goal Ca x P (OR 2.16, 95% CI 1.20-3.86, P = 0.0097). Transient hypercalcemia occurred in 8 of 48 (16.7%) calcium acetate recipients, all of whom received concomitant intravenous vitamin D. By regression analysis hypercalcemia was more likely with calcium acetate (OR 6.1, 95% CI 2.8-13.3, P < 0.0001). Week 8 intact PTH levels were not significantly different. Serum bicarbonate levels were significantly lower with sevelamer hydrochloride treatment (P < 0.0001). Conclusion. Calcium acetate controls serum phosphorus and calcium-phosphate product more effectively than sevelamer hydrochloride. Cost-benefit analysis indicates that in the absence of hypercalcemia, calcium acetate should remain the treatment of choice for hyperphosphatemia in hemodialysis patients.

KW - Calcium acetate

KW - Hypercalcemia

KW - Hyperphosphatemia

KW - Hypocalcemia

KW - Metabolic acidosis

KW - Sevelamer hydrochloride

UR - http://www.scopus.com/inward/record.url?scp=2342580138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342580138&partnerID=8YFLogxK

U2 - 10.1111/j.1523-1755.2004.00590.x

DO - 10.1111/j.1523-1755.2004.00590.x

M3 - Article

C2 - 15086935

AN - SCOPUS:2342580138

VL - 65

SP - 1914

EP - 1926

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -